Fermenta Biotech Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹133 Cr +1.9% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
FB

Fermenta Biotech Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Fermenta Biotech Q1 FY27: Capex ₹110 Cr

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹122Cr
−10.6% YoY
+0.2% QoQ
Net profit
₹10Cr
−55.9% YoY
−48.8% QoQ
Margin
14.83%
−5.9 pp YoY
−1.6 pp QoQ

Fermenta Biotech Ltd Q1 FY27 key numbers

Revenue
Revenue ex-real estate: INR 124.3 crore, down 12% YoY.

As stated in Fermenta Biotech Ltd's Q1 FY27 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on Fermenta Biotech Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹478
Market cap₹1.4K Cr
P/E25.5

The short version

Q1FY27 total revenue: INR 126.2 crore, down 13% YoY (Page 8) - Revenue ex-real estate: INR 124.3 crore, down 12% YoY (Page 5) - Nutrition business: - Vitamin D3 – Human Nutrition: INR 76.5 cro EBITDA: INR 22.4 crore in Q1FY27, down 39% YoY; INR 22.3 crore ex-real estate, down 37% YoY (Page 5) - Profit After Tax (PAT): INR 9.5 crore in Q1FY27, down 56% YoY (Page 5 and Page 8) - Year-on-Year Change: EBITDA down 39% YoY, PAT down 56% YoY (Page 5)

From Fermenta Biotech Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q1FY27 total revenue: INR 126.2 crore, down 13% YoY (Page 8)
  • Revenue ex-real estate: INR 124.3 crore, down 12% YoY (Page 5)
  • Nutrition business:
  • Vitamin D3 – Human Nutrition: INR 76.5 crore, down 10% YoY but up 24% QoQ (Page 7)
  • Vitamin D3 – Animal Nutrition: INR 12.6 crore, down 41% YoY and 45% QoQ (Page 7)
  • Others (Nutrition): INR 11.0 crore, up 28% YoY and 16% QoQ (Page 7)
  • Other APIs and Intermediates: INR 11.6 crore, up 18% YoY (Page 7)
  • Green Chemistry Solutions / Enzymes: INR 2.3 crore, up 15% YoY (Page 7)

2 more points from Fermenta Biotech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • ₹110 crore capex at Dahej for capacity committed to Spray-Dried Vitamin D3 Calcifediol scale-up (Page 16).
  • Dahej plant referenced for integrated, advanced manufacturing scale alongside Kullu and Tirupati (Page 12, 11).
  • Capacity scale-up at Dahej mentioned as a reason for increased employee costs ahead of the ramp-up (Page 9).
  • Launch readiness for Spray-Dried Vitamin D3 Calcifediol is approaching final validation as clinical demand opens (Page 16).

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Fermenta Biotech Ltd said on order book & pipeline — free account, 30 seconds.

Fermenta Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Fermenta Biotech Ltd Q1 FY27 results — key figures

Fermenta Biotech Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue122136-10.6%122+0.2%
Operating profit (EBITDA)1828-36%20-9.7%
Operating margin14.83%20.73%-5.9 pp16.45%-1.6 pp
Profit before tax1528-47.7%26-44%
Net profit (PAT)1022-55.9%19-48.8%
EPS (₹)3.317.42-55.4%6.52-49.2%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹133 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Fermenta Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Fermenta Biotech Ltd Q1 FY27 results?

Q1FY27 total revenue: INR 126.2 crore, down 13% YoY (Page 8) - Revenue ex-real estate: INR 124.3 crore, down 12% YoY (Page 5) - Nutrition business: - Vitamin D3 – Human Nutrition: INR 76.5 cro EBITDA: INR 22.4 crore in Q1FY27, down 39% YoY; INR 22.3 crore ex-real estate, down 37% YoY (Page 5) - Profit After Tax (PAT): INR 9.5 crore in Q1FY27, down 56% YoY (Page 5 and Page 8) - Year-on-Year Change: EBITDA down 39% YoY, PAT down 56% YoY (Page 5)

What is Fermenta Biotech Ltd share price analysis?

Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.

Is Fermenta Biotech Ltd planning capital expenditure?

₹110 crore capex at Dahej for capacity committed to Spray-Dried Vitamin D3 Calcifediol scale-up (Page 16).

Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.